<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253434</url>
  </required_header>
  <id_info>
    <org_study_id>E2022-J081-001</org_study_id>
    <nct_id>NCT01253434</nct_id>
  </id_info>
  <brief_title>E2022 Patch Formulation Single Dose Phase I Study</brief_title>
  <official_title>E2022 Patch Formulation Single Dose Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics of a single dose of E2022 in
      healthy Japanese male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label single site, randomized single dose study in 80 healthy Japanese
      male volunteers. The study consists of Period I to Period III, a total of 3 periods. In
      Period I, E2022 patches will be secured with seal. In Period II, single dose of E2022 5 mg
      tablet will be administered. In Period III, E2022 patches will be applied without seal. The
      features of the 5 patches will be evaluated in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of pharmacokinetics of E2022 patch (type A, B, C, D, E) with single dose of E2020 5 mg tablets.</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Japanese Healthy Male Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2022</intervention_name>
    <description>E2022 Type A patch</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2022</intervention_name>
    <description>E2022 Type B patch</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2022</intervention_name>
    <description>E2022 Type C patch</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2022</intervention_name>
    <description>E2022 Type D patch</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2022</intervention_name>
    <description>E2022 Type E patch</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Body Mass Index (BMI) at Screening is 18.5 kg/m2 or above and less than 25.0 kg/m2:
             BMI (kg/m2)= weight(kg) รท {height(m)ร height(m)}

          2. Subjects who are between 20 and 55 years of age at the time of obtaining written
             consent.

          3. Subjects who are willing to and can comply with the conditions described in the study
             protocol.

        Exclusion Criteria

          1. Subjects who consumed caffeine-containing food or beverages within 72 hours before
             study drug administration.

          2. Exposure to any supplements or herbs (including Chinese medicine), or beverages (e.g.
             alcohol or grapefruit-containing beverages) known to modulate CYP3A4, CYP2C9, CYP2C19,
             CYP2D6, within 2 weeks before study drug administration.

          3. Subjects with history of cutaneous hypersensitivity to external preparation, or those
             who are on another transdermal formulation.

          4. Subjects who have excessive skin hair around the region to put the patch on.

          5. Subjects with skin disorder, such as eczema, skin irritation, pigment disorder, injury
             or scar in the region of patch application, which may have an impact on skin findings.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomoo Ogawa</last_name>
    <role>Study Director</role>
    <affiliation>Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transdermal Administration</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

